Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1985 Apr;51(4):467–472. doi: 10.1038/bjc.1985.67

Chemotherapy of metastatic seminoma.

J Schuette, N Niederle, M E Scheulen, S Seeber, C G Schmidt
PMCID: PMC1977147  PMID: 2579665

Abstract

Response to chemotherapy and survival was retrospectively analyzed in 28 patients with bulky retroperitoneal and disseminated seminoma treated between 1977 and 1983. The median age was 41 years (range: 23-52). All patients had histological evidence of pure testicular seminoma, however, 14 patients revealed moderate increases of human beta-chorionic gonadotropin levels. Prior radiotherapy had been given to 9/28 (32%) patients. Treatment consisted of at least four courses of simultaneous or sequentially alternating therapy with cisplatin, vinblastine, bleomycin plus/minus adriamycin (PVB +/- A), administration of ifosfamide or combination therapy with ifosfamide/cisplatin (IFS/DDP) or ifosfamide/etoposide (IFS/ETP). Twenty-five of 28 patients (89%) achieved a complete (CR), and 3/28 patients a partial remission. Relapse occurred in 1/8 CR patients after adjuvant postchemotherapeutic irradiation, and in 1/11 patients without any further radiotherapy. So far, 23/28 patients (82%) are free of disease after a median follow-up of 28+ (14+----82+) months. Marked myelosuppression was observed in previously irradiated patients, mainly after PVB +/- A therapy. In two patients, transient nephrotoxicity developed after PVB and IFS/DDP, respectively. After PVB +/- A chemotherapy, three patients revealed polyneuropathy, paralytic subileus and bleomycin-induced pneumonitis, respectively. In conclusion, the present series suggests a high probability of continuous CR in even bulky retroperitoneal and widespread metastatic seminoma. So far, no definite conclusions can be made on the therapeutic superiority of one of the different chemotherapeutic regimens used. However, this preliminary experience suggests that the combination of ifosfamide and etoposide or cisplatin may prove less toxic than sequentially alternating or simultaneous PVB +/- A chemotherapy.

Full text

PDF
467

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BLOKHIN N., LARIONOV L., PEREVODCHIKOVA N., CHEBOTAREVA L., MERKULOVA N. [Clinical experiences with sarcolysin in neoplastic diseases]. Ann N Y Acad Sci. 1958 Apr 24;68(3):1128–1132. doi: 10.1111/j.1749-6632.1958.tb42675.x. [DOI] [PubMed] [Google Scholar]
  2. Ball D., Barrett A., Peckham M. J. The management of metastatic seminoma testis. Cancer. 1982 Dec 1;50(11):2289–2294. doi: 10.1002/1097-0142(19821201)50:11<2289::aid-cncr2820501112>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  3. CHEBOTAREVA L. I. LATE RESULTS OF SARCOLYSIN THERAPY IN TUMOURS OF THE TESTES. Acta Unio Int Contra Cancrum. 1964;20:380–381. [PubMed] [Google Scholar]
  4. Calman F. M., Peckman M. J., Hendry W. F. The pattern of spread and treatment of metastases in testicular seminoma. Br J Urol. 1979 Apr;51(2):154–160. doi: 10.1111/j.1464-410x.1979.tb02852.x. [DOI] [PubMed] [Google Scholar]
  5. Einhorn L. H., Donohue J. P. Combination chemotherapy in disseminated testicular cancer: the Indiana University experience. Semin Oncol. 1979 Mar;6(1):87–93. [PubMed] [Google Scholar]
  6. Einhorn L. H., Williams S. D. Chemotherapy of disseminated seminoma. Cancer Clin Trials. 1980;3(4):307–313. [PubMed] [Google Scholar]
  7. Golbey R. B. The place of chemotherapy in the treatment of testicular tumors. JAMA. 1970 Jul 6;213(1):101–passim. [PubMed] [Google Scholar]
  8. Javadpour N., McIntire K. R., Waldmann T. A. Human chorionic gonadotropin (HCG) and alpha-fetoprotein (AFP) in sera and tumor cells of patients with testicular seminoma: a prospective study. Cancer. 1978 Dec;42(6):2768–2772. doi: 10.1002/1097-0142(197812)42:6<2768::aid-cncr2820420636>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  9. Mackenzie A. R. The chemotherapy of metastatic seminoma. J Urol. 1966 Nov;96(5):790–793. doi: 10.1016/S0022-5347(17)63351-2. [DOI] [PubMed] [Google Scholar]
  10. Maier J. G., Mittemeyer B. T., Sulak M. H. Treatment and prognosis in seminoma of the testis. J Urol. 1968 Jan;99(1):72–78. doi: 10.1016/S0022-5347(17)62645-4. [DOI] [PubMed] [Google Scholar]
  11. Mauch P., Weichselbaum R., Botnick L. The significance of positive chorionic gonadotropins in apparently pure seminoma of the testis. Int J Radiat Oncol Biol Phys. 1979 Jun;5(6):887–889. doi: 10.1016/0360-3016(79)90073-7. [DOI] [PubMed] [Google Scholar]
  12. Mendenhall W. L., Williams S. D., Einhorn L. H., Donohue J. P. Disseminated seminoma: re-evaluation of treatment protocols. J Urol. 1981 Oct;126(4):493–496. doi: 10.1016/s0022-5347(17)54593-0. [DOI] [PubMed] [Google Scholar]
  13. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  14. Monfardini S., Bajetta E., Musumeci R., Bonadonna G. Clinical use of adriamycin in advanced testicular cancer. J Urol. 1972 Aug;108(2):293–296. doi: 10.1016/s0022-5347(17)60716-x. [DOI] [PubMed] [Google Scholar]
  15. Mostofi F. K. Proceedings: Testicular tumors. Epidemiologic, etiologic, and pathologic features. Cancer. 1973 Nov;32(5):1186–1201. doi: 10.1002/1097-0142(197311)32:5<1186::aid-cncr2820320527>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  16. Scheulen M. E., Seeber S., Schilcher R. B., Meier C. R., Schmidt C. G. Sequential combination chemotherapy with vinblastine-bleomycin and doxorubicin-cis-dichlorodiammineplatinum(II) in disseminated nonseminomatous testicular cancer. Cancer Treat Rep. 1980 Apr-May;64(4-5):599–609. [PubMed] [Google Scholar]
  17. Schütte J., Bremer K., Niederle N., Schoetensack B., Schmidt C. G., Seeber S. Sequentiell-alternierende Chemotherapie nicht-seminomatöser Hoden-tumoren mit Adriamycin/Cisplatin und Bleomycin/Vinblastin. Therapieansprechen und -versagen in Abhängigkeit von Histologie und Tumorstadium. Onkologie. 1983 Feb;6(1):16–20. doi: 10.1159/000215190. [DOI] [PubMed] [Google Scholar]
  18. Smith R. B., Dekernion J. B., Skinner D. G. Management of advanced testicular seminoma. J Urol. 1979 Apr;121(4):429–431. doi: 10.1016/s0022-5347(17)56811-1. [DOI] [PubMed] [Google Scholar]
  19. Thomas G. M., Rider W. D., Dembo A. J., Cummings B. J., Gospodarowicz M., Hawkins N. V., Herman J. G., Keen C. W. Seminoma of the testis: results of treatment and patterns of failure after radiation therapy. Int J Radiat Oncol Biol Phys. 1982 Feb;8(2):165–174. doi: 10.1016/0360-3016(82)90509-0. [DOI] [PubMed] [Google Scholar]
  20. Vugrin D., Whitmore W. F., Jr The VAB-6 regimen in the treatment of metastatic seminoma. Cancer. 1984 Jun 1;53(11):2422–2424. doi: 10.1002/1097-0142(19840601)53:11<2422::aid-cncr2820531110>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  21. Wajsman Z., Beckley S. A., Pontes J. E. Changing concepts in the treatment of advanced seminomatous tumors. J Urol. 1983 Feb;129(2):303–306. doi: 10.1016/s0022-5347(17)52066-2. [DOI] [PubMed] [Google Scholar]
  22. Whitmore W. F., Smith A., Yagoda A., Cvitkovic S. T., Golbey R. Chemotherapy of seminoma. Recent Results Cancer Res. 1977;(60):244–249. doi: 10.1007/978-3-642-81095-4_27. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES